Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children

administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.

integrase inhibitors
dolutegravir
antiretroviral therapy
hiv-1 rna measurement
antiviral drugs
  • 8 views
  • 08 Nov, 2020
A Study of Darunavir in Combination With Cobicistat or Ritonavir and Dabigatran Etexilate in Healthy Participants

The purpose of this study is to evaluate effect of single and repeated doses of darunavir (DRV) in combination with cobicistat (DRV/COBI) and with ritonavir (DRV+rtv) on the pharmacokinetics of

  • 5 views
  • 04 Nov, 2020
  • 1 location
Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Phase 4, single arm, open label study designed to compare the safety and efficacy of antiviral activity and immunological effect of Maraviroc in combination with Raltegravir and Darunavir

oophorectomy
reverse transcriptase inhibitor
antiviral
maraviroc
elisa
  • 24 views
  • 08 Nov, 2020
  • 1 location
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC

  • 0 views
  • 31 Dec, 2020
  • 33 locations
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

darunavir
antiretroviral agents
ritonavir
dolutegravir
antiretroviral therapy
  • 1 views
  • 22 Dec, 2019
  • 1 location
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir

darunavir
antiretroviral therapy
antiretroviral agents
ritonavir
dolutegravir
  • 1172 views
  • 11 Feb, 2020
  • 30 locations
Study Evaluating Pharmacokinetics (PK) Safety and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Virologically Suppressed Pediatric Participants

Cohort 1: The primary objectives are: To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted

emtricitabine
antiretroviral
cobicistat
atazanavir
tuberculosis
  • 236 views
  • 04 Jan, 2021
  • 37 locations
The Late Presenter Treatment Optimisation Study

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in

opportunistic infection
emtricitabine
cobicistat
HIV Infection
oophorectomy
  • 120 views
  • 12 Aug, 2019
  • 25 locations
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting changes in exposure (if any) …

  • 0 views
  • 29 Dec, 2020
  • 1 location
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamic of Oral Anticoagulants (Rivaroxaban Apixaban) in Health Volunteers

Background Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV

blood test
body mass index
fasting
  • 6 views
  • 19 Dec, 2020
  • 1 location